CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis

BackgroundCladribine has been introduced as a high-efficacy drug for treating relapsing-remitting multiple sclerosis (RRMS). Initial cohort studies showed early disease activity in the first year after drug initiation. Biomarkers that can predict early disease activity are needed.AimTo estimate cere...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Damiano Marastoni, Matteo Foschi, Chiara Eccher, Francesco Crescenzo, Valentina Mazziotti, Agnese Tamanti, Albulena Bajrami, Valentina Camera, Stefano Ziccardi, Maddalena Guandalini, Francesca Bosello, Daniela Anni, Federica Virla, Ermanna Turano, Michele Romoli, Raffaella Mariotti, Francesca Benedetta Pizzini, Bruno Bonetti, Massimiliano Calabrese
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2024-02-01
Serija:	Frontiers in Immunology
Teme:	relapsing multiple sclerosis cytokines chemokines cladribine disease activity biomarkers
Online dostop:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1343892/full
Oznake:	Označite Brez oznak, prvi označite!